Opening a niche for therapy: local lymphodepletion helps the immune system to fight melanoma
In this issue, Fujiwara et al. report that local ablation of CD4+ T cells in a murine B16 melanoma model, together with concomitant activation of the immune system by OX40L, leads to complete rejection of the melanomas. Rejection was driven mainly by CD8+ T cells, which infiltrated the melanomas and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2014
|
| In: |
The journal of investigative dermatology
Year: 2014, Volume: 134, Issue: 7, Pages: 1794-1796 |
| ISSN: | 1523-1747 |
| DOI: | 10.1038/jid.2014.100 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/jid.2014.100 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0022202X15369050 
|
| Author Notes: | Karsten Mahnke, Alexander Skorokhod, Stefan Grabbe and Alexander H. Enk |
| Summary: | In this issue, Fujiwara et al. report that local ablation of CD4+ T cells in a murine B16 melanoma model, together with concomitant activation of the immune system by OX40L, leads to complete rejection of the melanomas. Rejection was driven mainly by CD8+ T cells, which infiltrated the melanomas and secreted sizeable amounts of IFN-γ. However, CD8+ T-cell infiltration also caused the recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs). Although these cells did not prevent the rejection of the melanomas, in clinical settings the long-term repopulation of tumors by MDSCs may counteract successful treatment. Thus, local ablation of CD4+ leukocytes may improve anti-melanoma therapies in humans, but at the same time MDSC levels in the tumor cells have to be kept in check to ensure treatment success. |
|---|---|
| Item Description: | Available online 8 December 2015 Gesehen am 22.07.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1523-1747 |
| DOI: | 10.1038/jid.2014.100 |